LLY

808.07

0%↓

JNJ

155.14

-0.84%↓

ABBV

191.24

+0.99%↑

NVO

78.61

-0.99%↓

UNH

310.49

+2.21%↑

LLY

808.07

0%↓

JNJ

155.14

-0.84%↓

ABBV

191.24

+0.99%↑

NVO

78.61

-0.99%↓

UNH

310.49

+2.21%↑

LLY

808.07

0%↓

JNJ

155.14

-0.84%↓

ABBV

191.24

+0.99%↑

NVO

78.61

-0.99%↓

UNH

310.49

+2.21%↑

LLY

808.07

0%↓

JNJ

155.14

-0.84%↓

ABBV

191.24

+0.99%↑

NVO

78.61

-0.99%↓

UNH

310.49

+2.21%↑

LLY

808.07

0%↓

JNJ

155.14

-0.84%↓

ABBV

191.24

+0.99%↑

NVO

78.61

-0.99%↓

UNH

310.49

+2.21%↑

Search

Arbutus Biopharma Corp

Cerrado

3.51 -0.85

Resumen

Variación precio

24h

Actual

Mínimo

3.46

Máximo

3.59

Métricas clave

By Trading Economics

Ingresos

-12M

-25M

Ventas

190K

1.8M

BPA

-0.182

Margen de beneficio

-1,390.363

Empleados

44

EBITDA

-12M

-24M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+40.85% upside

Dividendos

By Dow Jones

Próximas Ganancias

31 jul 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

31M

672M

Apertura anterior

4.36

Cierre anterior

3.51

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

Arbutus Biopharma Corp Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

11 jun 2025, 22:03 UTC

Principales Movimientos del Mercado

Gamestop Shares Fall After Company Plans Convertible Notes Offering

11 jun 2025, 20:51 UTC

Ganancias

Oracle Shares Jump as CEO Targets 'Dramatically Higher' Revenue Growth Ahead

11 jun 2025, 23:46 UTC

Charlas de Mercado

Nikkei May Decline on Tariff Uncertainty, Stronger Yen -- Market Talk

11 jun 2025, 23:39 UTC

Charlas de Mercado

Gold Edges Higher Amid Geopolitical Tensions -- Market Talk

11 jun 2025, 22:16 UTC

Ganancias

Oracle Shares Jump With Target for Major Revenue Gains Ahead -- Update

11 jun 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

11 jun 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

11 jun 2025, 20:27 UTC

Ganancias

Chime Gets Set to Debut as IPO Market Starts to Heat Up -- Barrons.com

11 jun 2025, 20:27 UTC

Ganancias

These Stocks Moved the Most Today: Tesla, Cleveland-Cliffs, Quantum Computing, Oklo, SailPoint, Lockheed, and More -- Barrons.com

11 jun 2025, 20:10 UTC

Ganancias

Oracle Expects Triple-Digit MultiCloud Rev Growth to Continue in FY26 >ORCL

11 jun 2025, 20:09 UTC

Ganancias

Oracle: Cloud Infrastructure Growth Rate Is Expected to Increase From 50% in FY25 to Over 70% in FY26 >ORCL

11 jun 2025, 20:08 UTC

Ganancias

Oracle Expects Total Cloud Growth Rate--Applications Plus Infrastructure--Will Increase From 24% in FY25 to Over 40% in FY26 >ORCL

11 jun 2025, 20:08 UTC

Ganancias

Oracle Sees Revenue Growth Rates 'Dramatically Higher' in FY26 >ORCL

11 jun 2025, 20:08 UTC

Ganancias

Oracle 4Q Non-GAAP Operating Income Was $7 B >ORCL

11 jun 2025, 20:08 UTC

Ganancias

Oracle 4Q GAAP Operating Income Was $5.1 B >ORCL

11 jun 2025, 20:08 UTC

Ganancias

Oracle 4Q Remaining Performance Obligations $138 B >ORCL

11 jun 2025, 20:05 UTC

Ganancias

Oracle 4Q Rev $15.9B >ORCL

11 jun 2025, 20:05 UTC

Ganancias

Oracle 4Q Hardware Revenue $850M >ORCL

11 jun 2025, 20:05 UTC

Ganancias

Oracle 4Q Net $3.4B >ORCL

11 jun 2025, 20:05 UTC

Ganancias

Oracle 4Q Services Revenue $1.35B >ORCL

11 jun 2025, 20:05 UTC

Ganancias

Oracle 4Q Adj EPS $1.70 >ORCL

11 jun 2025, 20:05 UTC

Ganancias

Oracle 4Q Cloud License and On-Premise License Revenue $2.01B >ORCL

11 jun 2025, 20:05 UTC

Ganancias

Oracle 4Q EPS $1.19 >ORCL

11 jun 2025, 20:05 UTC

Ganancias

Oracle 4Q Cloud Services and License Support Revenue $11.7B >ORCL

11 jun 2025, 19:00 UTC

Charlas de Mercado

Oil Futures Soar on Raft of Supportive News -- Market Talk

11 jun 2025, 18:55 UTC

Charlas de Mercado

U.S. Natural Gas Futures Slip Ahead of Storage Data -- Market Talk

11 jun 2025, 18:49 UTC

Ganancias

These Stocks Are Moving the Most Today: Tesla, Cleveland-Cliffs, Quantum Computing, Oklo, SailPoint, Lockheed, and More -- Barrons.com

11 jun 2025, 18:22 UTC

Charlas de Mercado

Gold Flat After Tentative U.S.-China Trade Deal -- Market Talk

11 jun 2025, 18:19 UTC

Charlas de Mercado

UnitedHealth Seen on Longer Road to Recovery -- Market Talk

11 jun 2025, 18:08 UTC

Charlas de Mercado
Ganancias

Vera Bradley Leans on Retail Partnerships to Drive Engagement -- Market Talk

Comparación entre iguales

Cambio de precio

Arbutus Biopharma Corp Esperado

Precio Objetivo

By TipRanks

40.85% repunte

Estimación a 12 meses

Media 5 USD  40.85%

Máximo 5 USD

Mínimo 5 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Arbutus Biopharma Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

1 ratings

1

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

3.255 / 3.365Soporte y Resistencia

Corto Plazo

Weak Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Weak Bullish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.